Measles Vaccine in HCW

Kasr El Aini Hospital200 enrolled

Overview

Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV, The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19. We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

200

Conditions

Covid19

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-50 years old * Subjects who are willing to comply with the requirements of the study protocol and scheduled visits (for example, completion of the subject diary, return for follow-up visits) and who are willing to make themselves available for the duration of the study with access to a consistent means of telephone contact Exclusion Criteria: * acute severe illness * recent receipt of a blood product * history of thrombocytopenia * Pregnant females * any chronic medical condition * Any participant receiving any immune suppressive medication * Immunocompromised staff * Participants who have egg allergy * Participants who care for immune compromised hosts * Participants who test positive for COVID-19 serology prior to randomization

Outcomes

Primary Outcomes

COVID-19 disease incidence

Number of participants with asymptomatic or mild COVID-19 disease defined as fever (using self-reported questionnaire), plus at least one sign or symptom of respiratory disease including cough, runny/blocked nose (using self-reported questionnaire), plus positive SARS-Cov-2 test (PCR or serology)

Time frame: Time Frame: Measured over the 6 months following randomization

Secondary Outcomes

SARS-CoV-2 pneumonia

Number of pneumonia cases (abnormal chest X-ray) (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test

Time frame: Time Frame: Measured over the 6 months following randomization

Critical care admission duration with SARS-CoV-2

Number of days admitted to critical care (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test

Time frame: Time Frame: Measured over the 6 months following randomization

Oxygen therapy with SARS-CoV-2

Need for oxygen therapy (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test

Time frame: Time Frame: Measured over the 6 months following randomization

Measles Vaccine in HCW

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes